62 results on '"Myoblast transplantation"'
Search Results
2. In Vivo Myoblasts Tracking Using the Sodium Iodide Symporter Gene Expression in Dogs
- Author
-
Isabel Punzón, David Mauduit, Bryan Holvoet, Jean-Laurent Thibaud, Pauline de Fornel, Christophe M. Deroose, Nicolas Blanchard-Gutton, Jean-Thomas Vilquin, Maurilio Sampaolesi, Inès Barthélémy, and Stéphane Blot
- Subjects
myoblast transplantation ,sodium iodide symporter ,SPECT/CT ,in vivo imaging ,GRMD ,cell therapy ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Stem cell-based therapies are a promising approach for the treatment of degenerative muscular diseases; however, clinical trials have shown inconclusive and even disappointing results so far. Noninvasive cell monitoring by medicine imaging could improve the understanding of the survival and biodistribution of cells following injection. In this study, we assessed the canine sodium iodide symporter (cNIS) reporter gene as an imaging tool to track by single-photon emission computed tomography (SPECT/CT) transduced canine myoblasts after intramuscular (IM) administrations in dogs. cNIS-expressing cells kept their myogenic capacities and showed strong 99 mTc-pertechnetate (99 mTcO4−) uptake efficiency both in vitro and in vivo. cNIS expression allowed visualization of cells by SPECT/CT along time: 4 h, 48 h, 7 days, and 30 days after IM injection; biopsies collected 30 days post administration showed myofiber’s membranes expressing cNIS. This study demonstrates that NIS can be used as a reporter to track cells in vivo in the skeletal muscle of large animals. Our results set a proof of concept of the benefits NIS-tracking tool may bring to the already challenging cell-based therapies arena in myopathies and pave the way to a more efficient translation to the clinical setting from more accurate pre-clinical results.
- Published
- 2020
- Full Text
- View/download PDF
3. Muscle Stem Cell Biology and Implications in Gene Therapy
- Author
-
Partridge, Terence, Duan, Dongsheng, editor, and Mendell, Jerry R., editor
- Published
- 2019
- Full Text
- View/download PDF
4. HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway
- Author
-
Mariela Natacha González, Wallace de Mello, Gillian S. Butler-Browne, Suse Dayse Silva-Barbosa, Vincent Mouly, Wilson Savino, and Ingo Riederer
- Subjects
Myoblast transplantation ,HGF ,Migration ,Laminin ,Fibronectin ,Matrix metalloproteinases ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background The hepatocyte growth factor (HGF) is required for the activation of muscle progenitor cells called satellite cells (SC), plays a role in the migration of proliferating SC (myoblasts), and is present as a soluble factor during muscle regeneration, along with extracellular matrix (ECM) molecules. In this study, we aimed at determining whether HGF is able to interact with ECM proteins, particularly laminin 111 and fibronectin, and to modulate human myoblast migration. Methods We evaluated the expression of the HGF-receptor c-Met, laminin, and fibronectin receptors by immunoblotting, flow cytometry, or immunofluorescence and used Transwell assays to analyze myoblast migration on laminin 111 and fibronectin in the absence or presence of HGF. Zymography was used to check whether HGF could modulate the production of matrix metalloproteinases by human myoblasts, and the activation of MAPK/ERK pathways was evaluated by immunoblotting. Results We demonstrated that human myoblasts express c-Met, together with laminin and fibronectin receptors. We observed that human laminin 111 and fibronectin have a chemotactic effect on myoblast migration, and this was synergistically increased when low doses of HGF were added. We detected an increase in MMP-2 activity in myoblasts treated with HGF. Conversely, MMP-2 inhibition decreased the HGF-associated stimulation of cell migration triggered by laminin or fibronectin. HGF treatment also induced in human myoblasts activation of MAPK/ERK pathways, whose specific inhibition decreased the HGF-associated stimulus of cell migration triggered by laminin 111 or fibronectin. Conclusions We demonstrate that HGF induces ERK phosphorylation and MMP production, thus stimulating human myoblast migration on ECM molecules. Conceptually, these data state that the mechanisms involved in the migration of human myoblasts comprise both soluble and insoluble moieties. This should be taken into account to optimize the design of therapeutic cell transplantation strategies by improving the migration of donor cells within the host tissue, a main issue regarding this approach.
- Published
- 2017
- Full Text
- View/download PDF
5. Cell-based therapy for the treatment of female stress urinary incontinence: an early cost--effectiveness analysis.
- Author
-
Vilsbøll, Andreas West, Mouritsen, Jakob Munk, Jensen, Line Park, Bødker, Nikolaj, Holst, Annette Willemoes, Pennisi, Cristian P., and Ehlers, Lars
- Abstract
Aim: To perform an early cost--effectiveness analysis of in vitro expanded myoblasts (IVM) and minced myofibers versus midurethral slings (MUS) for surgical treatment of female stress urinary incontinence. Methods: Cost--effectiveness and sensitivity analyses were performed using a decision tree comprising previously published data and expert opinions. Results & conclusion: In the base case scenario, MUS was the cost-effective strategy with a negative incremental cost--effectiveness ratio compared with IVM and a positive incremental cost--effectiveness ratio compared with minced myofibers. However, the sensitivity analysis indicates that IVM may become an alternative providing greater effect at a higher cost. With the possibility of becoming more effective, IVM treatment would be advantageous over MUS given its reduced invasiveness and lower risks of complications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation
- Author
-
Dib, Nabil, Diethrich, Edward B., Campbell, Ann, Goodwin, Noreen, Robinson, Barb, Gilbert, James, Hobohm, Dan W., Taylor, Doris A., Dib, Nabil, editor, Taylor, Doris A., editor, and Diethrich, Edward B., editor
- Published
- 2006
- Full Text
- View/download PDF
7. Electrophysiological Aspects of Cell Transplantation
- Author
-
Peters, Nicholas S., Chronos, Nicolas A. F., Tondato, Fernando, Dib, Nabil, editor, Taylor, Doris A., editor, and Diethrich, Edward B., editor
- Published
- 2006
- Full Text
- View/download PDF
8. Myoblast Cell Transplantation: Preclinical Studies
- Author
-
Ott, Harald C., Taylor, Doris A., Dib, Nabil, editor, Taylor, Doris A., editor, and Diethrich, Edward B., editor
- Published
- 2006
- Full Text
- View/download PDF
9. Skeletal Myoblasts: The U.S. Experience
- Author
-
Diethrich, Edward B., Dib, Nabil, editor, Taylor, Doris A., editor, and Diethrich, Edward B., editor
- Published
- 2006
- Full Text
- View/download PDF
10. Skeletal Myoblast Transplantation for Cardiac Repair
- Author
-
Rosinberg, Audrey, Rana, Jamal S., Laham, Roger J., Cannon, Christopher P., editor, Laham, Roger J., editor, and Baim, Donald S., editor
- Published
- 2005
- Full Text
- View/download PDF
11. Cardiac Myoblasts
- Author
-
Menasché, P., Stock, G., editor, Lessl, M., editor, Keating, A., editor, Dicke, K., editor, Gorin, N., editor, Weber, R., editor, and Graf, H., editor
- Published
- 2005
- Full Text
- View/download PDF
12. Cellular Cardiac Reinforcement
- Author
-
Menasché, P., Doevendans, Pieter A., editor, and Kääb, Stefan, editor
- Published
- 2002
- Full Text
- View/download PDF
13. Cellular Transplantation for the Treatment of Heart Failure
- Author
-
Menasché, P., Haverich, A., editor, and Graf, H., editor
- Published
- 2002
- Full Text
- View/download PDF
14. HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway.
- Author
-
González, Mariela Natacha, de Mello, Wallace, Butler-Browne, Gillian S., Silva-Barbosa, Suse Dayse, Mouly, Vincent, Savino, Wilson, and Riederer, Ingo
- Subjects
HEPATOCYTE growth factor ,EXTRACELLULAR matrix ,MYOBLASTS ,MATRIX metalloproteinases ,MITOGEN-activated protein kinases ,FIBRONECTINS ,IMMUNOBLOTTING ,WESTERN immunoblotting - Abstract
Background: The hepatocyte growth factor (HGF) is required for the activation of muscle progenitor cells called satellite cells (SC), plays a role in the migration of proliferating SC (myoblasts), and is present as a soluble factor during muscle regeneration, along with extracellular matrix (ECM) molecules. In this study, we aimed at determining whether HGF is able to interact with ECM proteins, particularly laminin 111 and fibronectin, and to modulate human myoblast migration. Methods: We evaluated the expression of the HGF-receptor c-Met, laminin, and fibronectin receptors by immunoblotting, flow cytometry, or immunofluorescence and used Transwell assays to analyze myoblast migration on laminin 111 and fibronectin in the absence or presence of HGF. Zymography was used to check whether HGF could modulate the production of matrix metalloproteinases by human myoblasts, and the activation of MAPK/ERK pathways was evaluated by immunoblotting. Results: We demonstrated that human myoblasts express c-Met, together with laminin and fibronectin receptors. We observed that uman laminin 111 and fibronectin have a chemotactic effect on myoblast migration, and this was synergistically increased when low doses of HGF were added. We detected an increase in MMP-2 activity in myoblasts treated with HGF. Conversely, MMP-2 inhibition decreased the HGF-associated stimulation of cell migration triggered by laminin or fibronectin. HGF treatment also induced in human myoblasts activation of MAPK/ERK pathways, whose specific inhibition decreased the HGF-associated stimulus of cell migration triggered by laminin 111 or fibronectin. Conclusions: We demonstrate that HGF induces ERK phosphorylation and MMP production, thus stimulating human myoblast migration on ECM molecules. Conceptually, these data state that the mechanisms involved in the migration of human myoblasts comprise both soluble and insoluble moieties. This should be taken into account to optimize the design of therapeutic cell transplantation strategies by improving the migration of donor cells within the host tissue, a main issue regarding this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. Full-length Dysferlin Transfer by the Hyperactive Sleeping Beauty Transposase Restores Dysferlin-deficient Muscle
- Author
-
Helena Escobar, Verena Schöwel, Simone Spuler, Andreas Marg, and Zsuzsanna Izsvák
- Subjects
dysferlin ,gene therapy ,myoblast transplantation ,Sleeping Beauty transposon ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Dysferlin-deficient muscular dystrophy is a progressive disease characterized by muscle weakness and wasting for which there is no treatment. It is caused by mutations in DYSF, a large, multiexonic gene that forms a coding sequence of 6.2 kb. Sleeping Beauty (SB) transposon is a nonviral gene transfer vector, already used in clinical trials. The hyperactive SB system consists of a transposon DNA sequence and a transposase protein, SB100X, that can integrate DNA over 10 kb into the target genome. We constructed an SB transposon-based vector to deliver full-length human DYSF cDNA into dysferlin-deficient H2K A/J myoblasts. We demonstrate proper dysferlin expression as well as highly efficient engraftment (>1,100 donor-derived fibers) of the engineered myoblasts in the skeletal muscle of dysferlin- and immunodeficient B6. Cg-Dysfprmd Prkdcscid/J (Scid/BLA/J) mice. Nonviral gene delivery of full-length human dysferlin into muscle cells, along with a successful and efficient transplantation into skeletal muscle are important advances towards successful gene therapy of dysferlin-deficient muscular dystrophy.
- Published
- 2016
- Full Text
- View/download PDF
16. The DMD Gene Promoter: A Potential Role in Gene Therapy
- Author
-
Ray, Peter N., Klamut, Henry J., Worton, Ronald G., Griggs, Robert C., editor, and Karpati, George, editor
- Published
- 1990
- Full Text
- View/download PDF
17. Molecular Markers for Myoblast Transplantation in GRMD
- Author
-
Bartlett, R. J., Sharp, N. J. H., Hung, W.-Y., Kornegay, J. N., Roses, A. D., Griggs, Robert C., editor, and Karpati, George, editor
- Published
- 1990
- Full Text
- View/download PDF
18. Genetic and Biochemical Determinations in the Pre-Transplant Workup and in the Post-Transplant Assessment Period
- Author
-
Worton, Ronald G., Bulman, Dennis E., Zubrzycka-Gaarn, Elizabeth E., Ray, Peter N., Griggs, Robert C., editor, and Karpati, George, editor
- Published
- 1990
- Full Text
- View/download PDF
19. Localization of Muscle Gene Products in Nuclear Domains: Does this Constitute a Problem for Myoblast Therapy?
- Author
-
Blau, Helen M., Pavlath, Grace K., Rich, Kevin, Webster, Steven G., Griggs, Robert C., editor, and Karpati, George, editor
- Published
- 1990
- Full Text
- View/download PDF
20. In Vivo Myoblasts Tracking Using the Sodium Iodide Symporter Gene Expression in Dogs
- Author
-
David Mauduit, Stéphane Blot, Nicolas Blanchard-Gutton, Isabel Punzón, Maurilio Sampaolesi, Bryan Holvoet, Inès Barthélémy, Christophe Deroose, Jean-Thomas Vilquin, Jean-Laurent Thibaud, Pauline de Fornel, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), MICEN-Vet, Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), École nationale vétérinaire d'Alfort (ENVA), Université Paris-Est Marne-la-Vallée (UPEM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, and Centre de Recherche en Myologie
- Subjects
0301 basic medicine ,[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging ,[SDV]Life Sciences [q-bio] ,Research & Experimental Medicine ,THERAPY ,Cell therapy ,0302 clinical medicine ,Myocyte ,Medicine ,ComputingMilieux_MISCELLANEOUS ,lcsh:Cytology ,in vivo imaging ,DEATH ,3. Good health ,Medicine, Research & Experimental ,030220 oncology & carcinogenesis ,dog ,SKELETAL-MUSCLE ,Molecular Medicine ,GRMD ,Stem cell ,Life Sciences & Biomedicine ,STEM-CELLS ,Preclinical imaging ,Sodium-iodide symporter ,Biodistribution ,lcsh:QH426-470 ,REPORTER ,Article ,DUCHENNE MUSCULAR-DYSTROPHY ,03 medical and health sciences ,In vivo ,TOMOGRAPHY ,sodium iodide symporter ,Genetics ,lcsh:QH573-671 ,Molecular Biology ,Reporter gene ,Science & Technology ,TRANSPLANTATION ,business.industry ,SPECT/CT ,NIS ,lcsh:Genetics ,myoblast transplantation ,PET ,030104 developmental biology ,Cancer research ,cell therapy ,business - Abstract
Stem cell-based therapies are a promising approach for the treatment of degenerative muscular diseases; however, clinical trials have shown inconclusive and even disappointing results so far. Noninvasive cell monitoring by medicine imaging could improve the understanding of the survival and biodistribution of cells following injection. In this study, we assessed the canine sodium iodide symporter (cNIS) reporter gene as an imaging tool to track by single-photon emission computed tomography (SPECT/CT) transduced canine myoblasts after intramuscular (IM) administrations in dogs. cNIS-expressing cells kept their myogenic capacities and showed strong 99 mTc-pertechnetate (99 mTcO4−) uptake efficiency both in vitro and in vivo. cNIS expression allowed visualization of cells by SPECT/CT along time: 4 h, 48 h, 7 days, and 30 days after IM injection; biopsies collected 30 days post administration showed myofiber’s membranes expressing cNIS. This study demonstrates that NIS can be used as a reporter to track cells in vivo in the skeletal muscle of large animals. Our results set a proof of concept of the benefits NIS-tracking tool may bring to the already challenging cell-based therapies arena in myopathies and pave the way to a more efficient translation to the clinical setting from more accurate pre-clinical results., Graphical Abstract
- Published
- 2020
- Full Text
- View/download PDF
21. Retroviral Lineage Markers for Assessing Myoblast Fate In Vivo
- Author
-
Blau, Helen M., Hughes, Simon M., Griggs, Robert C., editor, and Karpati, George, editor
- Published
- 1990
- Full Text
- View/download PDF
22. Human muscular fetal cells: a potential cell source for muscular therapies.
- Author
-
Hirt-Burri, Nathalie, Buys Roessingh, Anthony, Scaletta, Corinne, Gerber, Stefan, Pioletti, Dominique, Applegate, Lee, Hohlfeld, Judith, de Buys Roessingh, Anthony S, Pioletti, Dominique P, and Applegate, Lee Ann
- Subjects
- *
MYOBLAST transfer therapy , *CARDIAC surgery , *TREATMENT of Duchenne muscular dystrophy , *THERAPEUTICS , *IMMUNE response , *MUSCLE cells , *MYOBLASTS , *STEM cell transplantation , *ANIMAL experimentation , *BIOPSY , *CELL culture , *CELL physiology , *COMPARATIVE studies , *CYTOSKELETAL proteins , *DNA , *GENES , *IMMUNOHISTOCHEMISTRY , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *MICROSCOPY , *MUSCULAR dystrophy , *POLYMERASE chain reaction , *RESEARCH , *STEM cells , *TISSUE engineering , *EVALUATION research , *REVERSE transcriptase polymerase chain reaction , *SKELETAL muscle , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Myoblast transfer therapy has been extensively studied for a wide range of clinical applications, such as tissue engineering for muscular loss, cardiac surgery or Duchenne Muscular Dystrophy treatment. However, this approach has been hindered by numerous limitations, including early myoblast death after injection and specific immune response after transplantation with allogenic cells. Different cell sources have been analyzed to overcome some of these limitations. The object of our study was to investigate the growth potential, characterization and integration in vivo of human primary fetal skeletal muscle cells. These data together show the potential for the creation of a cell bank to be used as a cell source for muscle cell therapy and tissue engineering. For this purpose, we developed primary muscular cell cultures from biopsies of human male thigh muscle from a 16-week-old fetus and from donors of 13 and 30 years old. We show that fetal myogenic cells can be successfully isolated and expanded in vitro from human fetal muscle biopsies, and that fetal cells have higher growth capacities when compared to young and adult cells. We confirm lineage specificity by comparing fetal muscle cells to fetal skin and bone cells in vitro by immunohistochemistry with desmin and 5.1 H11 antibodies. For the feasibility of the cell bank, we ensured that fetal muscle cells retained intrinsic characteristics after 5 years cryopreservation. Finally, human fetal muscle cells marked with PKH26 were injected in normal C57BL/6 mice and were found to be present up to 4 days. In conclusion we estimate that a human fetal skeletal muscle cell bank can be created for potential muscle cell therapy and tissue engineering. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
23. C2C12 skeletal muscle cells adopt cardiac-like sodium current properties in a cardiac cell environment.
- Author
-
Zebedin, Eva, Mile, Markus, Speiser, Maria, Zarrabi, Touran, Sandtner, Walter, Latzenhofer, Birgit, Todt, Hannes, and Hilber, Karlheinz
- Subjects
- *
MUSCLE cells , *MYOBLASTS , *MYOCARDIAL infarction , *HEART cells , *ARRHYTHMIA - Abstract
Intracardiac transplantation of undifferentiated skeletal muscle cells (myoblasts) has emerged as a promising therapy for myocardial infarct repair and is already undergoing clinical trials. The fact that cells originating from skeletal muscle have different electrophysiological properties than cardiomyocytes, however, may considerably limit the success of this therapy and, in addition, cause side effects. Indeed, a major problem observed after myoblast transplantation is the occurrence of ventricular arrhythmias. The most often transient nature of these arrhythmias may suggest that, once transplanted into cardiac tissue, skeletal muscle cells adopt more cardiac-like electrophysiological properties. To test whether a cardiac cell environment can indeed modify electrophysiological parameters of skeletal muscle cells, we treated mouse C2Cl2 myocytes with medium preconditioned by primary cardiocytes and compared their functional sodium current properties with those of control cells. We found this treatment to significantly alter the activation and inactivation properties of sodium currents from "skeletal muscle" to more "cardiac"-like ones. Sodium currents of cardiac-conditioned cells showed a reduced sensitivity to block by tetrodotoxin. These findings and reverse transcription PCR experiments suggest that an upregulation of the expression of the cardiac sodium channel isoform Nav1.5 versus the skeletal muscle isoform Nav1.4 is responsible for the observed changes in sodium current function. We conclude that cardiomyocytes alter sodium channel isoform expression of skeletal muscle cells via a paracrine mechanism. Thereby, skeletal muscle cells with more cardiac-like sodium current properties are generated. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
24. Exercise improves the success of myoblast transplantation in mdx mice
- Author
-
Bouchentouf, Manaf, Benabdallah, Basma F., Mills, Philippe, and Tremblay, Jacques P.
- Subjects
- *
DYSTROPHY , *NEUROMUSCULAR diseases , *MEMBRANE proteins , *DYSTROPHIN - Abstract
Abstract: Transplantation of normal muscle precursor cells is a potential approach to restore dystrophin expression within dystrophin [deficient] mdx mice, a model of Duchenne Muscular Dystrophy. This study aims to evaluate whether exercise could improve graft success and hybrid fiber distribution within mdx muscle. eGFP+ Muscle precursor cells were transplanted into tibialis anterior muscles of mdx mice using a single injection trajectory. During the following weeks, muscle fiber breaks were induced by making mdx mice swim. To evaluate fiber damage, Evans blue solution was injected intraperitoneally to mice 16h before their sacrifice. Tibialis anterior muscles were then harvested and eGFP, dystrophin and Evans blue labeling were analyzed by fluorescent microscopy. Twenty minutes of exercise (i.e., swimming) were used to induce damage in about 30% of TA muscle fibers. Graft success, evaluated as the percentage of hybrid fibers which are eGFP+, was improved by 1.9-fold after swimming 3 times per week during 4 weeks and by 1.8-fold after daily swimming. Hybrid muscle fiber transversal and longitudinal distribution were also increased after repeated physical efforts. Exercise induced fiber breaks, which improved MPC recruitment and fusion and increased long-term graft success and also transverse and longitudinal distribution of hybrid fibers. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
25. Myogenic stem cells: regeneration and cell therapy in human skeletal muscle
- Author
-
Negroni, E., Butler-Browne, G.S., and Mouly, V.
- Subjects
- *
STEM cells , *CELLULAR therapy , *HUMAN skeleton , *DYSTROPHY - Abstract
Abstract: Human skeletal muscle has been considered as an ideal target for cell-mediated therapy. However, the positive results obtained in dystrophic animal models using the resident precursor satellite cell population have been followed by discouraging evidences obtained in the clinical trials involving Duchenne muscular dystrophy patients. This text reviews the recent advances that many groups have achieved to identify from the stem cell compartment putative candidates for cell therapy. We focused our attention on stem cells with myogenic potential which might be able to improve transplantation efficiency and therefore could be used as a therapeutic tool for neuromuscular diseases. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
26. The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy.
- Author
-
Mouly, V., Aamiri, A., Bigot, A., Cooper, R. N., Di Donna, S., Furling, D., Gidaro, T., Jacquemin, V., Mamchaoui, K., Negroni, E., Périé, S., Renault, V., Silva-Barbosa, S. D., and Butler-Browne, G. S.
- Subjects
- *
MUSCLES , *REGENERATION (Biology) , *SATELLITE cells , *CELL proliferation , *TELOMERES , *CELL cycle - Abstract
The regenerative capacity of skeletal muscle will depend on the number of available satellite cells and their proliferative capacity. We have measured both parameters in ageing, and have shown that although the proliferative capacity of satellite cells is decreasing during muscle growth, it then stabilizes in the adult, whereas the number of satellite cells decreases during ageing. We have also developed a model to evaluate the regenerative capacity of human satellite cells by implantation into regenerating muscles of immunodeficient mice. Using telomere measurements, we have shown that the proliferative capacity of satellite cells is dramatically decreased in muscle dystrophies, thus hampering the possibilities of autologous cell therapy. Immortalization by telomerase was unsuccessful, and we currently investigate the factors involved in cell cycle exits in human myoblasts. We have also observed that insulin-like growth factor-1 (IGF-1), a factor known to provoke hypertrophy, does not increase the proliferative potential of satellite cells, which suggests that hypertrophy is provoked by increasing the number of satellite cells engaged in differentiation, thus possibly decreasing the compartment of reserve cells. We conclude that autologous cell therapy can be applied to specific targets when there is a source of satellite cells which is not yet exhausted. This is the case of Oculo–Pharyngeal Muscular Dystrophy (OPMD), a late onset muscular dystrophy, and we participate to a clinical trial using autologous satellite cells isolated from muscles spared by the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
27. Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies
- Author
-
Wiendl, Heinz, Mitsdoerffer, Meike, and Weller, Michael
- Subjects
- *
MYOBLAST transfer therapy , *MUSCLE diseases , *PATHOLOGICAL physiology , *HLA histocompatibility antigens - Abstract
Muscle is the site or the target of immunologic injury in several diseases. Whereas under physiologic conditions muscle fibers are negative for major histocompatibility complex (MHC) class I antigens, these are upregulated under pathologic conditions, thus rendering muscle a possible target for the recognition by cytotoxic CD8 T cells. Cultured muscle cells are capable of presenting antigens to CD4 and CD8 T cells, further indicating that muscle fibers in vivo are critically involved in the initiating or perpetuating steps of inflammatory responses. The finding that muscle fibers in autoimmune inflammatory myopathies in vivo and cultured muscle cells in vitro express the nonclassical major histocompatibility complex molecule HLA-G raises several hypothesis concerning its possible pathophysiologic role. We review present knowledge on the functional consequences of muscle-related HLA-G and provide concepts of its relevance under pathologic conditions. We further speculate on the potential therapeutic implications of HLA-G that relate to special approaches such as myoblast transplantation or strategies against inflammatory aggression in general. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
28. Efficacy of Myoblast Transplantation in Nonhuman Primates Following Simple Intramuscular Cell Injections: Toward Defining Strategies Applicable to Humans
- Author
-
Skuk, Daniel, Goulet, Marlyne, Roy, Brigitte, and Tremblay, Jacques P.
- Subjects
- *
MYOBLASTS , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Nonhuman primates were used to define myoblast transplantation strategies applicable to humans. Nevertheless, previous experiments were based on the use of myotoxins concomitant with the myoblast injections. Since myotoxins must be avoided for clinical applications, we analyzed the efficacy of simple myoblast injections (i.e., myoblasts resuspended only in saline) into monkey muscles. We also evaluated different FK506 dosages (in combination or not with mycophenolate mofetil) for immunosuppression. Allogeneic myoblasts transduced with the β-galactosidase (β-Gal) gene were implanted in the muscles of 19 monkeys by injections placed 1 to 2 mm from each other. A biopsy was performed at the implanted sites 1 month later, and histologically studied for demonstration of β-Gal+ myofibers, lymphocyte infiltration, and CD8+ cells. The presence of antibodies against the donor myoblasts and the blood levels of FK506 were analyzed. Our results show that: (1) If myoblast injections are sufficiently close to each other, high percentages of hybrid myofibers can be obtained following myoblast transplantation in primates (25 to 67% with an interinjection distance of 1 mm). (2) Efficient immunosuppression can be reached by increasing FK506 dosages, but also by combining this drug with mycophenolate mofetil, a combination that reduces toxic effects. The present results represent a step towards a better designing of myoblast transplantation strategies in humans. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
29. Combined Notch and PDGF Signaling Enhances Migration and Expression of Stem Cell Markers while Inducing Perivascular Cell Features in Muscle Satellite Cells
- Author
-
Mattia Francesco Maria Gerli, Louise Anne Moyle, Sara Benedetti, Giulia Ferrari, Ekin Ucuncu, Martina Ragazzi, Chrystalla Constantinou, Irene Louca, Hiroshi Sakai, Pierpaolo Ala, Paolo De Coppi, Shahragim Tajbakhsh, Giulio Cossu, and Francesco Saverio Tedesco
- Subjects
perivascular cells ,PERICYTES ,Muscle Development ,Biochemistry ,MYOBLAST TRANSPLANTATION ,Myoblasts ,Mice ,Cell Movement ,Receptors, Platelet-Derived Growth Factor ,lcsh:QH301-705.5 ,satellite cells ,lcsh:R5-920 ,muscle regeneration ,Receptors, Notch ,Stem Cells ,Intracellular Signaling Peptides and Proteins ,SMOOTH-MUSCLE ,NICHE ,PDGF ,Up-Regulation ,NOTCH ,DIFFERENTIATION ,SKELETAL-MUSCLE ,GROWTH ,lcsh:Medicine (General) ,Life Sciences & Biomedicine ,Signal Transduction ,stem cell fate ,muscular dystrophy ,Satellite Cells, Skeletal Muscle ,DISTINCT ,Article ,Cell & Tissue Engineering ,Genetics ,Animals ,Humans ,Regeneration ,Muscle, Skeletal ,Science & Technology ,Endothelial Cells ,Membrane Proteins ,reprogramming ,Cell Biology ,GENE ,Mice, Inbred C57BL ,muscle stem cells ,lcsh:Biology (General) ,PROGENITOR CELLS ,cell therapy ,Pericytes ,Biomarkers ,Developmental Biology - Abstract
Summary Satellite cells are responsible for skeletal muscle regeneration. Upon activation, they proliferate as transient amplifying myoblasts, most of which fuse into regenerating myofibers. Despite their remarkable differentiation potential, these cells have limited migration capacity, which curtails clinical use for widespread forms of muscular dystrophy. Conversely, skeletal muscle perivascular cells have less myogenic potential but better migration capacity than satellite cells. Here we show that modulation of Notch and PDGF pathways, involved in developmental specification of pericytes, induces perivascular cell features in adult mouse and human satellite cell-derived myoblasts. DLL4 and PDGF-BB-treated cells express markers of perivascular cells and associate with endothelial networks while also upregulating markers of satellite cell self-renewal. Moreover, treated cells acquire trans-endothelial migration ability while remaining capable of engrafting skeletal muscle upon intramuscular transplantation. These results extend our understanding of muscle stem cell fate plasticity and provide a druggable pathway with clinical relevance for muscle cell therapy., Graphical Abstract, Highlights • DLL4 and PDGF-BB change satellite cell morphology, proliferation, and differentiation • DLL4 and PDGF-BB induce both perivascular and satellite cell gene expression • Treated satellite cells acquire perivascular cell properties and improved migration • Human satellite cell-derived myoblasts respond to DLL4 and PDGF-BB treatment, Gerli and Moyle and colleagues show that treatment with molecules involved in developmental specification of pericytes (DLL4 and PDGF-BB) alters satellite cell fate and provides them with features potentially relevant for novel cell therapy protocols.
- Published
- 2019
- Full Text
- View/download PDF
30. Stable hybrid myotubes: A new model for studying re-expression of enzymatic activities in vitro.
- Author
-
Meola, G., Sansone, V., Rotondo, G., Radice, S., Bottiroli, G., and Scarlato, G.
- Abstract
Copyright of Italian Journal of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 1993
- Full Text
- View/download PDF
31. Cell-based therapy for the treatment of female stress urinary incontinence:an early cost–effectiveness analysis
- Author
-
Vilsbøll, Andreas Westh, Mouritsen, Jakob Munk, Jensen, Line Park, Bødker, Nikolaj, Holst, Annette Willemoes, Pennisi, Cristian Pablo, and Ehlers, Lars Holger
- Subjects
myoblast transplantation ,midurethral slings ,incremental cost-effectiveness ratio ,stress urinary incontinence ,cell- and tissue-based therapy ,economic analysis ,healthcare costs - Abstract
Aim: To perform an early cost-effectiveness analysis of in vitro expanded myoblasts (IVM) and minced myofibers versus midurethral slings (MUS) for surgical treatment of female stress urinary incontinence. Methods: Cost-effectiveness and sensitivity analyses were performed using a decision tree comprising previously published data and expert opinions. Results & conclusion: In the base case scenario, MUS was the cost-effective strategy with a negative incremental cost-effectiveness ratio compared with IVM and a positive incremental cost-effectiveness ratio compared with minced myofibers. However, the sensitivity analysis indicates that IVM may become an alternative providing greater effect at a higher cost. With the possibility of becoming more effective, IVM treatment would be advantageous over MUS given its reduced invasiveness and lower risks of complications.
- Published
- 2018
- Full Text
- View/download PDF
32. A cell-based gene therapy approach for dysferlinopathy using Sleeping Beauty transposon
- Author
-
Escobar Fernández, Helena
- Subjects
myoblast transplantation ,Sleeping Beauty transposon ,gene therapy ,dysferlin - Abstract
Miyoshi myopathy (MM), limb girdle muscular dystrophy 2B (LGMD2B) and distal anterior compartment myopathy (DACM) are rare autosomal recessive muscle disorders caused by mutations in dysferlin. They are encompassed by the term dysferlinopathy and affect the proximal and/or distal muscles of the limbs. Patients usually become wheelchair bound within 15 years of disease onset due to progressive muscle degeneration, weakness and atrophy. No treatment is available. The dysferlin gene spans over 150 kb of genomic DNA in chromosome 2p13 and comprises 55 exons that form a coding sequence of 6.2 kb. Dysferlin is a 237 kDa protein of the ferlin family. It is expressed in many tissues, but more strongly in muscle, where it is found in mature myofibers and to some extent also in satellite cells and myoblasts. It has important roles in membrane repair and in maintaining the transverse tubule structure in myofibers. Besides alterations of these two functions, defects in dysferlin cause increased inflammatory attack to muscle fibers thereby enhancing the muscle pathology. Muscle regeneration relies on muscle stem cells, called satellite cells, and their progeny of muscle precursors, the myoblasts. Upon muscle injury caused by severe trauma or muscle disorders, they are capable of extensive proliferation to repair the damaged tissue. Satellite cells are marked by the expression of the transcription factor Pax7, they can be isolated based on specific surface markers and have a robust engraftment potential when transplanted into regenerating muscles. Therefore, autologous or allogeneic satellite cell and myoblast transplantation are envisioned as promising therapeutic alternatives. Given that a single gene is causative for dysferlinopathy, gene therapy also holds great promise. However, the large size of the full-length dysferlin coding sequence represents a challenge for gene transfer approaches because most viral vectors used in gene therapy have a lower cargo capacity. Sleeping Beauty transposon is a non-viral bi-component vector system consisting of a transposon DNA sequence and a transposase protein. The transposase excises the transposon from a donor plasmid and integrates it into the target genome. Since the transposon can be engineered to carry any sequence of interest, Sleeping Beauty is very valuable as a genetic tool for stable gene transfer and has been widely used in gene therapy. Sleeping Beauty system can be used to integrate transgenes up to ~8 kb with high efficiency. It is therefore well-suited for delivery of full- length dysferlin. In this work, I developed a non-viral cell-based gene therapy approach for dysferlinopathy. Using Sleeping Beauty transposon, I transferred the full-length human dysferlin cDNA into dysferlin deficient H2K A/J mouse myoblasts, leading to restoration of dysferlin protein expression in vitro. I transplanted the corrected myoblasts into dysferlin deficient Scid/blAJ mice following local irradiation of the recipient muscles. This step was necessary to ablate the endogenous satellite cells and promote engraftment of the transplanted cells. I found up to ~90 dysferlin expressing myofibers 3 and 6 weeks post-transplantation. Inducing regeneration in the recipient muscles simultaneously to cell transplantation by injection of cardiotoxin, a snake venom toxin that causes acute damage to myofibers, further enhanced engraftment of the donor cells. In muscles treated with cardiotoxin in addition to irradiation, I found up to ~1000 donor-derived myofibers 3 and 6 weeks after grafting, which were present almost along the entire length of the muscles. Moreover, I found numerous Pax7+ cells in the vicinity of donor- derived myofibers in the grafted muscles. Given that recipient muscles were irradiated prior to grafting, this suggests that donor myoblasts were able to repopulate the host satellite cell compartment upon transplantation. Engraftment as satellite cells would ensure long-term contribution of donor- derived cells to muscle regeneration. These results show the feasibility of long-term full-length dysferlin reconstitution in skeletal muscle through ex vivo gene transfer with Sleeping Beauty., Miyoshi Myopathie (MM), Gliedergürteldystrophie Typ 2B (engl. limb girdle muscular dystrophy 2B, LGMD2B) und die DACM (distal anterior compartment myopathy) sind seltene, autosomal rezessiv vererbte Krankheiten, die durch Mutationen im Dysferlin-Gen verursacht werden. Diese muskulären Erkrankungen werden unter dem Begriff Dysferlinopathie zusammengefasst und betreffen die proximale und/oder die distale Muskulatur der Extremitäten. Durch eine zunehmende Schwächung und Atrophie der Muskeln sind Patienten normalerweise bereits 15 Jahre nach Krankheitsbeginn an den Rollstuhl gebunden. Behandlungsmöglichkeiten gibt es hier keine. Das Dysferlin-Gen umfasst einen 150 kb-Bereich der genomischen DNA auf Chromosom 2p13 und beinhaltet 55 Exons mit einer kodierenden Sequenz von 6,2 kb. Dysferlin ist ein 237 kDa Protein der Ferlinfamilie. Es ist in vielen Geweben vorhanden, vor allem im Muskelgewebe, wo es in ausgereiften Muskelfasern, aber auch in Satellitenzellen und Myoblasten exprimiert wird. Dysferlin spielt eine wichtige Rolle bei der Membranreparatur und der Aufrechterhaltung der T-Tubuli Struktur in den Muskelfasern. Auβer dem erhöht sich durch ein defektes Dysferlinprotein die Entzündungsanfälligkeit der Muskelfasern. Die Regenerationsfähigkeit von Muskeln beruht auf den Muskelstammzellen (Satellitenzellen) und ihren Abkömmlingen, den Muskelvorläuferzellen (Myoblasten). Bei Muskelverletzungen, z.B. durch schwere Verwundungen oder durch Muskelerkrankungen, vermehren sich diese Zellen extensiv um das geschädigte Gewebe zu reparieren. Satellitenzellen sind durch die Expression des Transkriptionsfaktors Pax7 gekennzeichnet. Ihre Isolation basiert auf spezifischen Oberflächenmarkern. Zudem haben sie ein hohes Anwachspotential, wenn sie in sich regenerierendes Muskelgewebe tranplantiert werden. Deshalb gilt die autologe oder allogene Transplantation von Satellitenzellen oder Myoblasten als vielversprechende therapeutische Alternative. Da Dysferlinopathien durch ein einzelnes Gen verursacht werden, ist zudem die Gentherapie hier sehr erfolgversprechend. Allerdings werden Gentransferversuche durch die Gröβe der kodierenden Dysferlinsequenz erschwert, da die meisten viralen Vektoren, welche für Gentherapiezwecke benutzt werden, eine zu geringe Ladungskapazität besitzen. Das Sleeping Beauty Transposon ist ein nicht-virales 2-Komponenten Vektorsystem, welches aus der DNA Sequenz des Transposons und einem Transposase Protein besteht. Die Transposase schneidet das Transposon aus dem Donorplasmid heraus und integriert es in das Zielgenom. Da das Transposon so verändert werden kann, dass es jede Zielsequenz beinhalten kann, ist Sleeping Beauty ein sehr wichtiges, nicht-virales, genetisches Werkzeug, das einen stabilen Gentransfer ermöglicht und deshalb häufig in der Gentherapie verwendet wird. Durch das Sleeping Beauty System kann ein bis zu 8 kb groβes Transgen effizient integriert werden. Damit ist es auch für die Integration des vollständigen Dysferlin-Gens sehr gut geeignet. Im Rahmen dieser Arbeit habe ich eine Methode entwickelt, welche einen nicht-viralen zellbasierten Ansatz zur Gentherapie von Dysferlinopathien ermöglicht. Durch Nutzung des Sleeping Beauty Transposons ist es mir gelungen, die vollständige humane Dysferlin cDNA-Sequenz in Dysferlin-defiziente H2K A/J Myoblasten der Maus zu transferieren und die Dysferlinexpression in vitro wieder herzustellen. Die so korrigierten Myoblasten habe ich in Dysferlin-defiziente Scid/blAJ Mäuse transplantiert, in denen der Empfängermuskel zuvor lokal bestrahlt wurde. Dieser Schritt war notwendig, um die Anzahl der endogenen Satellitenzellen zu verringern und das Anwachsen der transplantierten Zellen zu fördern. 3-6 Wochen nach der Transplantation konnte ich eine Dysferlinexpression in bis zu 90 Muskelfasern nachweisen. Eine gleichzeitig zur Transplantation stattfindende Injektion des Zellgiftes Cardiotoxin führte zu einem wesentlich verbesserten Anwachsen der Donorzellen. Muskeln, welche zusätzlich zur Bestrahlung noch mit Cardiotoxin geschädigt wurden, wiesen 3 bis 6 Wochen nach der Transplantation bis zu 1000 Dysferlin exprimierende Muskelfasern auf. Zudem konnte ich in den transplantierten Muskeln eine Vielzahl von Pax7 positiven Zellen in der Umgebung der von den Spenderzellen abgeleiteten Myofibrillen identifizieren. Da der Empfängermuskel vor der Transplantation bestrahlt wurde, deutet dieses darauf hin, dass das Satellitenzellkompartiment des Empfängermuskels nach der Transplantation wieder neu besiedelt wurde. Das Anwachsen der Myoblasten als Satellitenzellen würde daher einen dauerhaften Beitrag der Spenderzellen zur Regeneration des Muskels belegen. Diese Ergebnisse zeigen, dass eine Rekonstruktion des vollständigen Dysferlin Proteins in Skelettmuskeln durch Sleeping Beauty vermittelten Gentransfer möglich ist.
- Published
- 2015
- Full Text
- View/download PDF
33. Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo
- Author
-
Cantini, M., Giurisato, E., Radu, C., Tiozzo, S., Pampinella, F., Senigaglia, D., Zaniolo, G., Mazzoleni, F., and Vitiello, L.
- Published
- 2002
- Full Text
- View/download PDF
34. Dynamics of Myoblast Transplantation Reveal a Discrete Minority of Precursors with Stem Cell–like Properties as the Myogenic Source
- Author
-
Charles N. Pagel, Terence A. Partridge, Jonathan R. Beauchamp, and Jennifer E. Morgan
- Subjects
Cell division ,cell heterogeneity ,Cell Survival ,Cell Transplantation ,Cellular differentiation ,Biology ,Mice ,Tissue culture ,Animals ,Myocyte ,mdx mouse ,skeletal muscle ,Muscle, Skeletal ,Cell Death ,Stem Cells ,Cell Differentiation ,Cell Biology ,Muscular Dystrophy, Animal ,Cell cycle ,Clone Cells ,Cell biology ,Transplantation ,myoblast transplantation ,Immunology ,Mice, Inbred mdx ,Female ,Stem cell ,C2C12 ,Cell Division ,Regular Articles ,Stem Cell Transplantation - Abstract
Myoblasts, the precursors of skeletal muscle fibers, can be induced to withdraw from the cell cycle and differentiate in vitro. Recent studies have also identified undifferentiated subpopulations that can self-renew and generate myogenic cells (Baroffio, A., M. Hamann, L. Bernheim, M.-L. Bochaton-Pillat, G. Gabbiani, and C.R. Bader. 1996. Differentiation. 60:47–57; Yoshida, N., S. Yoshida, K. Koishi, K. Masuda, and Y. Nabeshima. 1998. J. Cell Sci. 111:769–779). Cultured myoblasts can also differentiate and contribute to repair and new muscle formation in vivo, a capacity exploited in attempts to develop myoblast transplantation (MT) for genetic modification of adult muscle. Our studies of the dynamics of MT demonstrate that cultures of myoblasts contain distinct subpopulations defined by their behavior in vitro and divergent responses to grafting. By comparing a genomic and a semiconserved marker, we have followed the fate of myoblasts transplanted into muscles of dystrophic mice, finding that the majority of the grafted cells quickly die and only a minority are responsible for new muscle formation. This minority is behaviorally distinct, slowly dividing in tissue culture, but rapidly proliferative after grafting, suggesting a subpopulation with stem cell–like characteristics.
- Published
- 1999
- Full Text
- View/download PDF
35. Matching host muscle and donor myoblasts for myosin heavy chain improves myoblast transfer therapy
- Author
-
Qu, Z and Huard, J
- Published
- 2000
- Full Text
- View/download PDF
36. Myoblast transplantations lead to the expression of the laminin α2 chain in normal and dystrophic (dy/dy) mouse muscles
- Author
-
Vilquin, J-T, Guérette, B, Puymirat, J, Yaffe, D, Tomé, F M S, Fardeau, M, Fiszman, M, Schwartz, K, and Tremblay, J P
- Published
- 1999
- Full Text
- View/download PDF
37. Development of Approaches to Improve Cell Survival in Myoblast Transfer Therapy
- Author
-
Judith C.T. van Deutekom, Zhuqing Qu, Levent Balkir, Paul D. Robbins, Johnny Huard, and Ryan Pruchnic
- Subjects
Cell Survival ,medicine.medical_treatment ,Duchenne muscular dystrophy ,Muscle Proteins ,Desmin ,Mice ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,Myocyte ,gene transfer ,Muscle, Skeletal ,Cells, Cultured ,030304 developmental biology ,Inflammation ,0303 health sciences ,biology ,Gene Transfer Techniques ,Receptors, Interleukin-1 ,Skeletal muscle ,Articles ,adenovirus ,Cell Biology ,musculoskeletal system ,medicine.disease ,Immunohistochemistry ,Molecular biology ,muscle derived stem cells ,Cell biology ,Transplantation ,myoblast transplantation ,Disease Models, Animal ,Cytokine ,medicine.anatomical_structure ,Animals, Newborn ,Cell culture ,Tissue Transplantation ,Mice, Inbred mdx ,biology.protein ,Dystrophin ,030217 neurology & neurosurgery - Abstract
Myoblast transplantation has been extensively studied as a gene complementation approach for genetic diseases such as Duchenne Muscular Dystrophy. This approach has been found capable of delivering dystrophin, the product missing in Duchenne Muscular Dystrophy muscle, and leading to an increase of strength in the dystrophic muscle. This approach, however, has been hindered by numerous limitations, including immunological problems, and low spread and poor survival of the injected myoblasts. We have investigated whether antiinflammatory treatment and use of different populations of skeletal muscle–derived cells may circumvent the poor survival of the injected myoblasts after implantation. We have observed that different populations of muscle-derived cells can be isolated from skeletal muscle based on their desmin immunoreactivity and differentiation capacity. Moreover, these cells acted differently when injected into muscle: 95% of the injected cells in some populations died within 48 h, while others richer in desmin-positive cells survived entirely. Since pure myoblasts obtained from isolated myofibers and myoblast cell lines also displayed a poor survival rate of the injected cells, we have concluded that the differential survival of the populations of muscle-derived cells is not only attributable to their content in desmin-positive cells. We have observed that the origin of the myogenic cells may influence their survival in the injected muscle. Finally, we have observed that myoblasts genetically engineered to express an inhibitor of the inflammatory cytokine, IL-1, can improve the survival rate of the injected myoblasts. Our results suggest that selection of specific muscle-derived cell populations or the control of inflammation can be used as an approach to improve cell survival after both myoblast transplantation and the myoblast-mediated ex vivo gene transfer approach.
- Published
- 1998
- Full Text
- View/download PDF
38. Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts
- Author
-
Moisset, P-A, Gagnon, Y, Karpati, G, and Tremblay, JP
- Published
- 1998
- Full Text
- View/download PDF
39. Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes
- Author
-
Fu, Tong-Ming, Ulmer, Jeffrey B., Caulfield, Michael J., Deck, R. Randall, Friedman, Arthur, Wang, Su, Liu, Xu, Donnelly, John J., Liu, Margaret A., and Wigzell, H.
- Published
- 1997
- Full Text
- View/download PDF
40. Dystrophin-positive muscle fibers following C2 myoblast transplantation into mdx nude mice
- Author
-
Hagiwara, Yasuko, Mizuno, Yuji, Takemitsu, Masakazu, Matsuzaki, Tetsuya, Nonaka, Ikuya, and Ozawa, Eijiro
- Published
- 1995
- Full Text
- View/download PDF
41. Growth, differentiation, transplantation and survival of human skeletal myofibers on biodegradable scaffolds
- Author
-
Lieven Thorrez, Janet Shansky, Herman H. Vandenburgh, Thierry VandenDriessche, Lin Wang, Loren D. Fast, David J. Mooney, Marinee Chuah, Division of Gene Therapy & Regenerative Medicine, and Cell Biology and Histology
- Subjects
muscle ,Cell Transplantation ,Cellular differentiation ,Cell Culture Techniques ,biodegradation ,angiogenesis ,Mice ,Absorbable Implants ,Myocyte ,Musculoskeletal System ,Cells, Cultured ,education.field_of_study ,SISTA ,Cell Differentiation ,tension ,Cell biology ,Extracellular Matrix ,Killer Cells, Natural ,medicine.anatomical_structure ,Mechanics of Materials ,stem-cell engraftment ,Materials science ,gene-therapy ,muscle tissue ,Cell Survival ,Population ,Biophysics ,Bioengineering ,in-vitro ,Article ,Biomaterials ,In vivo ,medicine ,Animals ,Humans ,education ,cell viability ,poly-lactide-co-glycolide ,Severe combined immunodeficiency ,scid mice ,receptor-gamma chain ,Skeletal muscle ,medicine.disease ,factor delivery ,Transplantation ,cell differentiation ,myoblast transplantation ,Immunology ,Ceramics and Composites ,immunodeficient mouse model ,Ex vivo - Abstract
Skeletal muscle transplantation strategies for muscle repair or gene therapy involve either the injection of proliferating myoblasts followed by fusion with host myofibers or implantation of ex vivo differentiated myofibers; however, both implant procedures are associated with significant cell loss. Biodegradable porous, gas-foamed poly-lactide-co-glycolide (PLG) scaffolds have desirable characteristics for cell transfer and were used to study attachment, growth, differentiation and survival of human myogenic cells. Primary human myoblasts suspended in clinical grade extracellular matrixes (ECMs) and adhered to PLG scaffolds differentiated in vitro into high-density tropomyosin positive myofibers. An immunodeficient non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse implant model was used to study the transfer and in vivo survival of differentiated human myofibers on these scaffolds. Scaffold rigidity allowed the myofibers to be maintained under tension in vitro and following subcutaneous transplantation in vivo. Following implantation, myofiber density on the PLG scaffolds decreased linearly by 78% over a 4-week period. ECM composed of either Tisseel((R)) fibrin or Zyderm((R)) collagen type I did not significantly affect in vivo cell viability over the 4-week period. Varying PLG scaffold microsphere content (10-100%) also had little effect on cell survival in vivo. In contrast, when the residual NK cell population in the immunodeficient NOD/SCID mouse model was depleted with anti-asialo GM1 (ASGM1) antiscrum, in vivo cell survival significantly increased from 22% to 34% after 4 weeks. With further improvements in cell survival, PLG scaffolds may prove useful for the implantation of primary human myofibers in future clinical applications. (c) 2007 Elsevier Ltd. All rights reserved. ispartof: Biomaterials vol:29 issue:1 pages:75-84 ispartof: location:Netherlands status: published
- Published
- 2008
42. Enhancing myoblast proliferation by using myogenic factors: a promising approach for improving fiber regeneration in sport medicine and skeletal muscle diseases
- Author
-
Vitiello, Libero, Radu, CLAUDIA-MARIA, Malerba, Alberto, Segat, Daniela, Cantini, Marcello, Carraro, Ugo, and Baroni, MAURIZIO DAVID
- Subjects
muscle regeneration ,myoblast transplantation ,macrophages - Published
- 2004
43. Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo
- Author
-
C. Radu, Emanuele Giurisato, Giovanna Zaniolo, D. Senigaglia, Libero Vitiello, Francesco Mazzoleni, Marcello Cantini, Francesca Pampinella, and Stefano Tiozzo
- Subjects
Muscle tissue ,Male ,Soft Tissue Injuries ,Dermatology ,Biology ,Cell Line ,Myoblasts ,Mice ,In vivo ,macrophages ,cytokines ,muscle regeneration ,myoblast transplantation ,medicine ,Myocyte ,Macrophage ,Animals ,Humans ,Rats, Wistar ,Growth Substances ,Muscle, Skeletal ,Transcription factor ,Proliferative capacity ,Cell Differentiation ,General Medicine ,In vitro ,Cell biology ,Rats ,Psychiatry and Mental health ,Disease Models, Animal ,medicine.anatomical_structure ,Cell culture ,Culture Media, Conditioned ,Immunology ,Neurology (clinical) ,Cell Division - Abstract
In this work we set out to determine if the murine macrophage J774 cell line can be used to produce myogenic growth factors. Activated J774 macrophages were grown in serum-free conditions. The macrophage-conditioned medium (MCM) was then used to treat cultures of primary myoblasts and regenerating muscle tissue, in vitro and in vivo respectively. MCM activity in vitro was tested by analyzing the expression of muscle-specific transcription factors, in parallel with the proliferation and differentiation rates of the cells. The macrophage-secreted factors greatly enhanced the proliferative potential of both rat and human primary myoblasts and were found to be highly muscle-specific. In vivo, MCM administration markedly enhanced the regenerative processes in damaged muscles. The ability to produce large amounts of macrophage-secreted myogenic factor(s) in the absence of serum holds great promise for its biochemical characterization and successive application in therapeutic protocols, both for ex vivo gene therapy and for muscle repair.
- Published
- 2002
44. Promotion of muscle regeneration by myoblast transplantation combined with the controlled and sustained release of bFGFcpr.
- Author
-
Hagiwara K, Chen G, Kawazoe N, Tabata Y, and Komuro H
- Subjects
- Animals, Cell Survival drug effects, Delayed-Action Preparations, Fluorescent Antibody Technique, Gene Expression Regulation drug effects, Green Fluorescent Proteins metabolism, Muscle Fibers, Skeletal drug effects, Muscle Fibers, Skeletal physiology, Muscle, Skeletal drug effects, Myoblasts cytology, Myoblasts drug effects, Myogenic Regulatory Factors genetics, Myogenic Regulatory Factors metabolism, Neovascularization, Physiologic drug effects, Neovascularization, Physiologic genetics, Platelet Endothelial Cell Adhesion Molecule-1 genetics, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Rats, Sprague-Dawley, Fibroblast Growth Factor 2 administration & dosage, Fibroblast Growth Factor 2 pharmacology, Muscle, Skeletal physiology, Myoblasts transplantation, Regeneration
- Abstract
Although myoblast transplantation is an attractive method for muscle regeneration, its efficiency remains limited. The efficacy of myoblast transplantation in combination with the controlled and sustained delivery of basic fibroblast growth factor (bFGF) was investigated. Defects of thigh muscle in Sprague-Dawley (SD) rats were created, and GFP-positive myoblasts were subsequently transplanted. The rats were divided into three groups. In control group 1 (C1) only myoblasts were transplanted, while in control group 2 (C2) myoblasts were introduced along with empty gelatin hydrogel microspheres. In the experimental group (Ex), myoblasts were transplanted along with bFGF incorporated into gelatin hydrogel microspheres. Four weeks after transplantation, GFP-positive myoblasts were found to be integrated into the recipient muscle and to contribute to muscle fibre regeneration in all groups. A significantly higher expression level of GFP in the Ex group demonstrated that the survival rate of transplanted myoblasts in Ex was remarkably improved compared with that in C1 and C2. Furthermore, myofibre regeneration, characterized by centralization of the nuclei, was markedly accelerated in Ex. The expression level of CD31 in Ex was higher than that in both C1 and C2, but the differences were not statistically significant. A significantly higher expression level of Myogenin and a lower expression level of MyoD1 were both observed in Ex after 4 weeks, suggesting the promotion of differentiation to myotubes. Our findings suggest that the controlled and sustained release of bFGF from gelatin hydrogel microspheres improves the survival rate of transplanted myoblasts and promotes muscle regeneration by facilitating myogenesis rather than angiogenesis., (Copyright © 2013 John Wiley & Sons, Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
45. MMP1 gene expression enhances myoblast migration and engraftment following implanting into mdx/SCID mice.
- Author
-
Pan H, Vojnits K, Liu TT, Meng F, Yang L, Wang Y, Huard J, Cox CS, Lally KP, and Li Y
- Subjects
- Animals, Female, Matrix Metalloproteinase 13 genetics, Mice, Mice, Inbred C57BL, Mice, Inbred mdx, Mice, SCID, Cell Movement physiology, Matrix Metalloproteinase 13 metabolism, Myoblasts cytology, Myoblasts metabolism
- Abstract
Myoblast transplantation (MT) is a method to introduce healthy genes into abnormal skeletal muscle. It has been considered as a therapeutic modality in the last few decades for diseases such as Duchenne Muscular Dystrophy (DMD). However, challenges including cell death and poor graft engraftment have limited its application. The current experiment utilizes MMP1 gene transfer to improve the efficacy of myoblast transplantation into the diseased dystrophic skeletal muscle of mdx mice. Our results indicated that MMP1 expression can promote myogenic differentiation and fusion capacities, increase migration of MMP1 expressing myoblasts in vitro, as well as improve engraftment of dystrophin positive myofibers in vivo. Taken together, our observation suggests that the addition of MMP1 can overcome limitations in MT and improve its clinical efficacy.
- Published
- 2015
- Full Text
- View/download PDF
46. The cardiac regenerative potential of myoblasts remains limited despite improving their survival via antioxidant treatment.
- Author
-
Beckman SA, Sekiya N, Chen WCW, Mlakar L, Tobita K, and Huard J
- Abstract
Introduction: Since myoblasts have been limited by poor cell survival after cellular myoplasty, the major goal of the current study was to determine whether improving myoblast survival with an antioxidant could improve cardiac function after the transplantation of the myoblasts into an acute myocardial infarction., Background: We previously demonstrated that early myogenic progenitors such as muscle-derived stem cells (MDSCs) exhibited superior cell survival and improved cardiac repair after transplantation into infarcted hearts compared to myoblasts, which we partially attributed to MDSC's higher antioxidant levels., Aim: To determine if antioxidant treatment could increase myoblast survival, subsequently improving cardiac function after myoblast transplantation into infarcted hearts., Materials and Methods: Myoblasts were pre-treated with the antioxidant N-acetylcysteine (NAC) or the glutathione depleter, diethyl maleate (DEM), and injected into infarcted murine hearts. Regenerative potential was monitored by cell survival and cardiac function., Results: At early time points, hearts injected with NAC-treated myoblasts exhibited increased donor cell survival, greater cell proliferation, and decreased cellular apoptosis, compared to untreated myoblasts. NAC-treated myoblasts significantly improved cardiac contractility, reduced fibrosis, and increased vascular density compared to DEM-treated myoblasts, but compared to untreated myoblasts, no difference was noted., Discussion: While early survival of myoblasts transplanted into infarcted hearts was augmented by NAC pre-treatment, cardiac function remained unchanged compared to non-treated myoblasts., Conclusion: Despite improving cell survival with NAC treated myoblast transplantation in a MI heart, cardiac function remained similar to untreated myoblasts. These results suggest that the reduced cardiac regenerative potential of myoblasts, when compared to MDSCs, is not only attributable to cell survival but is probably also related to the secretion of paracrine factors by the MDSCs., Competing Interests: Conflict of Interests Johnny Huard received consulting fees and royalty payments from Cook MyoSite, Inc. during the period of time in which this project was performed.
- Published
- 2014
47. Intramuscular Migration of Myoblasts Transplanted after Muscle Pretreatment with Metalloproteinases.
- Author
-
Torrente Y, Fahime EE, Caron NJ, Bresolin N, and Tremblay JP
- Abstract
The effect of pretreatments of host muscles with metalloproteinases (MMPs) or with notexin on the migration of transplanted myoblasts was investigated. Transgenic TnILacZ mice in which the β-galactosidase gene is under the control of a quail fast skeletal troponin I gene promoter were used as donors. A polyethylene microtube with four perforations was inserted in the tibialis anterior (TA) of CD1 mice. Both pretreatment substances and cells were slowly injected through that microtube. Muscles were pretreated 2 days before myoblast injection either with a mixture of collagenase, matrilysin, and notexin or with only collagenase and matrilysin or only notexin. As control for our experiments, TnILacZ and C2C12 myoblasts were also injected in TA muscles not pretreated. Comparison of short and long-term myoblast radial migration was performed using a dye (PKH26) and X-gal staining, respectively. The recipient mice were immunosuppressed with FK506. Two days after myoblast transplantation, the cell movement in muscles pretreated with collagenase, matrilysin, and notexin was slightly greater than in muscles pretreated only with collagenase and matrilysin but was about twice that observed in muscles treated with notexin alone. Almost no radial migration of TnILacZ myoblasts was observed in untreated muscles. The C2C12 myoblasts showed a four-to fivefold higher migration capacity than TnILacZ myoblasts. At 15 days after TnILacZ myoblast transplantation, the farthest positive β-gal muscle fibers show a two- to threefold extension of the initial migration observed at 2 days, demonstrating the ability of myoblasts to continue the migration following all pretreatments and even in the untreated muscles. In addition, more muscle fibers expressed the β-gal reporter gene in muscles pretreated only with MMPs. Our results clearly demonstrate that muscle pretreatments with MMPs increase myoblast migration and fusion with host muscle fibers after transplantation and that the C2C12 cell line producing MMPs has a higher migratory capacity.
- Published
- 2000
- Full Text
- View/download PDF
48. Proliferative Dynamics and the Role of FGF2 During Myogenesis of Rat Satellite Cells on Isolated Fibers.
- Author
-
Yablonka-Reuveni Z and Rivera AJ
- Abstract
Myogenic precursors in adult skeletal muscle (satellite cells) are mitotically quiescent but can proliferate in response to a variety of stresses including muscle injury. To gain further understanding of adult myoblasts, we are analyzing myogenesis of satellite cells on fibers isolated from adult rat muscle. In this culture model, satellite cells are maintained in their in situ position underneath the fiber basement membrane. Employing two different approaches to monitor proliferation of satellite cells on isolated fibers (autoradiography following
3 H-thymidine incorporation and immunofluorescence of cells positive for proliferating cell nuclear antigen (PCNA)), we show in the present study that satellite cells initiate cell proliferation at 12 to 24 hours following fiber culture establishment and that cell proliferation is reduced to minimal levels by 60 to 72 hours in culture. Maximal number of proliferating cells is seen at 36 to 48 hours in culture. These PCNA+ satellite cells transit into the differentiated, myogenin+ state following about 24 hours in the proliferative state. Continuous exposure of the fiber culture to FGF2 (basic FGF; added at the time of culture establishment) leads to a 2 fold increase in the number of PCNA+ cells by 48 hours in culture but the overall schedule of proliferation and transition into the myogenin+ state is not affected. Delaying the addition of FGF2 until 15 to 18 hours following the initiation of the fiber culture does not reduce its effect. However, the addition of FGF2 at 24 hours or later results in a progressive reduction in the number of proliferating satellite cells. Exposure of fiber cultures to transforming growth factor β (TGFβ1) leads to a reduction in the number of proliferating cells in both the absence or presence of FGF2. We propose that FGF2 enhances the number of proliferating cells by facilitating the recruitment of additional satellite cells from the quiescent state. However, satellite cells on isolated fibers conform to a highly coordinated program and rapidly transit from proliferation to differentiation regardless of the presence of FGF. The identification of agents that can prolong the proliferative state of satellite cells when the cells undergo myogenesis in their native position by the intact myofiber might be useful in improving myoblast transplantation into skeletal muscle for cell-mediated gene therapy.- Published
- 1997
49. Human muscular fetal cells: a potential cell source for muscular therapies
- Author
-
Judith Hohlfeld, Anthony de Buys Roessingh, Lee Ann Applegate, Nathalie Hirt-Burri, S. Gerber, Dominique P. Pioletti, and Corinne Scaletta
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Adolescent ,Fetal cells ,Cell Survival ,Biopsy ,Myoblasts, Skeletal ,Duchenne muscular dystrophy ,Cell ,Muscular Dystrophies ,Cell therapy ,Desmin ,Mice ,Pregnancy ,medicine ,Animals ,Humans ,Myocyte ,Tissue engineering ,Muscle, Skeletal ,Cells, Cultured ,Myoblast transplantation ,Reverse Transcriptase Polymerase Chain Reaction ,business.industry ,Gene Expression Regulation, Developmental ,Skeletal muscle ,DNA ,General Medicine ,medicine.disease ,Immunohistochemistry ,DNA/genetics ,Desmin/biosynthesis ,Desmin/genetics ,Female ,Mice, Inbred C57BL ,Microscopy, Fluorescence ,Muscle, Skeletal/embryology ,Muscle, Skeletal/metabolism ,Muscular Dystrophies/surgery ,Myoblasts, Skeletal/cytology ,Myoblasts, Skeletal/metabolism ,Stem Cell Transplantation/methods ,Tissue Engineering/methods ,medicine.anatomical_structure ,Cell culture ,Pediatrics, Perinatology and Child Health ,Muscle ,Surgery ,business ,Cell bank ,Stem Cell Transplantation - Abstract
Myoblast transfer therapy has been extensively studied for a wide range of clinical applications, such as tissue engineering for muscular loss, cardiac surgery or Duchenne Muscular Dystrophy treatment. However, this approach has been hindered by numerous limitations, including early myoblast death after injection and specific immune response after transplantation with allogenic cells. Different cell sources have been analyzed to overcome some of these limitations. The object of our study was to investigate the growth potential, characterization and integration in vivo of human primary fetal skeletal muscle cells. These data together show the potential for the creation of a cell bank to be used as a cell source for muscle cell therapy and tissue engineering. For this purpose, we developed primary muscular cell cultures from biopsies of human male thigh muscle from a 16-week-old fetus and from donors of 13 and 30 years old. We show that fetal myogenic cells can be successfully isolated and expanded in vitro from human fetal muscle biopsies, and that fetal cells have higher growth capacities when compared to young and adult cells. We confirm lineage specificity by comparing fetal muscle cells to fetal skin and bone cells in vitro by immunohistochemistry with desmin and 5.1 H11 antibodies. For the feasibility of the cell bank, we ensured that fetal muscle cells retained intrinsic characteristics after 5 years cryopreservation. Finally, human fetal muscle cells marked with PKH26 were injected in normal C57BL/6 mice and were found to be present up to 4 days. In conclusion we estimate that a human fetal skeletal muscle cell bank can be created for potential muscle cell therapy and tissue engineering.
50. Dynamics of Myoblast Transplantation Reveal a Discrete Minority of Precursors with Stem Cell-like Properties as the Myogenic Source
- Author
-
Beauchamp, Jonathan R., Morgan, Jennifer E., Pagel, Charles N., and Partridge, Terence A.
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.